ArticleEuropean endodontic journal2025
Human Stem Cells of Apical Papilla Viability Following the Removal of Triple Antibiotic Paste in a 3D Root Canal Culture Model.
Article in European endodontic journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated the residual effects of various concentrations of triple antibiotic paste (TAP) on the viability of human stem cells of the apical papilla (hSCAPs) in a 3D root canal culture model.
methodsSixty-four single-rooted segments were prepared and allocated into five groups (n=12): four concentrations of TAP (1 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 mg/ml) and a control group with vehicle alone. TAP was prepared by mixing USP-graded antibiotic powder with vehicle (macrogol and propylene glycol). The canals were filled with the prepared medication for 28 days. After removing TAP, fibrin gels containing hSCAPs were loaded into the canal and incubated for 7 days. Cell morphology was observed using confocal laser scanning microscopy (CLSM), whilst cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) assay.
resultsThe vehicle alone and the 1 mg/ml TAP groups showed viable and proliferative cell morphology. However, higher concentrations of TAP displayed non-proliferative cells as observed by CLSM. For the cell viability test, 1 mg/ml TAP did not demonstrate a different percentage of cell viability from the control group. However, 2.5 mg/ml, 5 mg/ml and 10 mg/ml TAP exhibited significantly lower percentages of cell viability compared with the control (p<0.001).
conclusionCells can survive at low TAP concentrations of ≤1 mg/ml. However, harmful effects become evident at TAP concentrations of ≥2.5 mg/ml.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.